Similarly, Roach et al. [47] conducted a prospective multi-center study involving 431 prostate cancer patients across four Australian centers, which demonstrated the significant clinical impact of 68Ga-PSMA PET/CT. This evidence concerns the gene FOLH1 and prostate carcinoma.